OW
SummitIn person
3rd Obesity & Weight Loss Drug Development Summit West
Hosted by Hanson Wade
- 9 – 10 December 2026
Add to calendar
Welcome to kongre.net - Hilton San Diego Mission Valley, San Diego, United States of America
- Medical & Health SciencesBasic MedicinePharmacology & Toxicology
Let others know you'll be there. This does not register you for the event.
Welcome to kongre.net
Welcome to kongre.net
Key facts
3rd Obesity & Weight Loss Drug Development Summit West is a summit held 9 – 10 December 2026 in Hilton San Diego Mission Valley, San Diego, United States of America, organised by Hanson Wade.
- Dates:
- 9 – 10 December 2026
- Format:
- In person
- Venue:
- Hilton San Diego Mission Valley, San Diego, United States of America
- Subjects:
- Medical & Health Sciences, Pharmacology & Toxicology
- Organiser:
- Hanson Wade
- Official website:
- obesity-weight-loss-west.com
The 3rd Obesity & Weight Loss Drug Development Summit West is an industry-focused forum bringing together pharma and biotech leaders to discuss practical challenges, strategic decisions, and next-generation therapeutics in obesity drug development. The event focuses on tolerability, muscle preservation, patient adherence, and precision medicine.
Conference theme
Shaping the Next Wave of Obesity Therapeutics & Emerging Market Opportunities
Objectives
To benchmark strategies, evaluate emerging mechanisms and combination approaches, improve tolerability and muscle preservation, and navigate the evolving competitive landscape in obesity therapeutics.
Who should attend
Senior executives, pharma and biotech leaders, and obesity drug development professionals.
Organising Committee
Abigail Dufeu - Program Director
Andrew Kennard - Marketing Executive
Edward O'Keefe - Partnerships Manager
Mollie Hookway - Event Manager
Programme highlights
View full programmeSpeakers
View all 12 speakersPatrick Griffin
Incregen Therapeutics
Fireside Chat: Aligning Route & Frequency of Administration with Real-World Patient Needs & Treatment GoalsMini Balakrishnan
Biomea Fusion
Beyond Glycemic Control: Advancing Icovamenib as a Potential Disease- Modifying Therapy for Diabetes & ObesityHarshini Neelakantan
Ridgeline Therapeutics
Preserving Muscle Strength to Maximize the Impact of GLP-1s in Obesity ManagementAshok Bhandari
Protagonist Therapeutics
Discovery & Preclinical Development of PN-477, Next-Generation Oral Triple-G Agonist for Obesity
Organiser and contact
Contact
- Email:
- [email protected]
Advertisement
Related events
- CNS 2026 Annual MeetingWashington, D.C., United States of America31 Oct 2026 – 4 Nov 2026
- 25th Annual Pain Medicine MeetingTampa, United States of America5–7 Nov 2026
- ASDS Annual MeetingSan Diego, United States of America5–8 Nov 2026
- The Liver Meeting 2026Denver, United States of America5–9 Nov 2026
- 28th Asia-Pacific League of Associations for Rheumatology CongressSeoul, South Korea28 Oct 2026 – 1 Nov 2026
- 55th International Scientific Congress of the Turkish Periodontology AssociationBelek, Türkiye29 Oct 2026 – 1 Nov 2026